Sanofi ROE 2010-2024 | SNY

Current and historical return on equity (ROE) values for Sanofi (SNY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Sanofi ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-03-31 $4.93B 12.33%
2023-12-31 $5.84B $80.47B 14.61%
2023-09-30 $9.68B 24.39%
2023-06-30 $9.02B $79.54B 22.73%
2023-03-31 $8.71B 22.46%
2022-12-31 $8.82B $79.18B 22.75%
2022-09-30 $8.33B 43.90%
2022-03-31 $6.88B 36.02%
2021-09-30 $6.90B 36.16%
2021-03-31 $7.99B inf%
2020-09-30 $7.39B inf%
2020-03-31 $6.36B inf%
2019-09-30 $4.98B 30.24%
2019-03-31 $4.86B 29.50%
2018-03-31 $4.71B 14.55%
2017-12-31 $9.53B $65.85B 29.46%
2017-09-30 $9.90B 31.05%
2017-06-30 $9.92B $63.58B 31.13%
2017-03-31 $10.09B 32.21%
2016-12-31 $5.21B $63.88B 16.64%
2016-09-30 $6.19B 40.31%
2016-06-30 $5.76B $61.39B 18.55%
2016-03-31 $5.52B 16.49%
2015-09-30 $4.90B 9.45%
2015-06-30 $4.59B $62.80B 6.57%
2014-06-30 $5.57B $71.01B 10.27%
2013-06-30 $6.39B $73.39B 11.39%
2012-06-30 $8.61B $72.42B 22.81%
2012-03-31 $8.56B $0.00B 22.19%
2011-12-31 $9.33B $78.54B 24.20%
2011-09-30 $8.04B 21.95%
2011-06-30 $7.45B $75.69B 20.36%
2011-03-31 $8.22B 23.85%
2010-12-31 $8.24B $70.76B 23.90%
2010-09-30 $9.30B 27.63%
2010-06-30 $10.37B $67.09B 30.81%
2010-03-31 $11.38B 35.40%
2009-12-31 $10.99B $67.56B 34.20%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $119.456B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Innoviva (INVA) United States $1.013B 7.11